Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Fineline Cube Jan 26, 2026
Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Fineline Cube Jan 23, 2026
Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Fineline Cube Jan 23, 2026
Company Deals

BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector

Fineline Cube Jan 23, 2026
Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Fineline Cube Jan 26, 2026
Company Drug

Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study

Fineline Cube Jan 26, 2026
Company Deals

Porton Pharma and Dragon Sail Join Forces to Enhance ADC Drug Development

Fineline Cube Dec 24, 2024

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has entered into a strategic...

Company Drug

GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial

Fineline Cube Dec 23, 2024

UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44...

Company Drug

Pfizer’s Braftovi Receives FDA Approval for Metastatic Colorectal Cancer Treatment

Fineline Cube Dec 23, 2024

US-based Pfizer (NYSE: PFE) has announced receiving an indication extension approval from the US Food...

Company Drug

Eli Lilly’s Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity

Fineline Cube Dec 23, 2024

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has revealed that the US Food...

Company Drug

Novo Nordisk’s Alhemo Receives FDA Approval for Hemophilia A and B Prophylaxis

Fineline Cube Dec 23, 2024

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced that the US Food and Drug Administration...

Company

Boehringer Ingelheim-SEC Joint Incubator Launches in Shenzhen’s Luohu District

Fineline Cube Dec 23, 2024

On December 23, the Boehringer Ingelheim-SEC Joint innovative incubator was inaugurated in Luohu District, Shenzhen....

Company Drug

CStone Pharmaceuticals Initiates First-in-Human Trial for PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009

Fineline Cube Dec 23, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has announced the clinical filing for its CS2009, a PD-1/VEGF/CTLA-4...

Company Medical Device

Becton, Dickinson and Co. Launches RMB1.332 Billion Factory in Jiangsu for Pre-Filled Syringes

Fineline Cube Dec 23, 2024

US-based Becton, Dickinson and Co., (BD) has officially put into operation its new factory in...

Company Deals

C.Q. Pharmaceutical Holding to Come Under SASAC’s Indirect Control via Genertec Acquisition

Fineline Cube Dec 23, 2024

C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a Chongqing-based pharmaceutical company, is set to be...

Company Drug

Yifan Pharmaceutical’s Evive Biotech Receives ANVISA Approval for Ryzneuta

Fineline Cube Dec 23, 2024

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary, Evive Biotech Ltd,...

Company Drug

Changchun BCHT Biotechnology Receives NMPA Approval for HSV-2 mRNA Vaccine LVRNA101

Fineline Cube Dec 23, 2024

Changchun BCHT Biotechnology Co., Ltd (SHA: 688276), a China-based biotechnology company, has announced receiving clinical...

Company Drug

Shenzhen Chipscreen Biosciences Gets NMPA Approval for CS231295 Solid Tumor Study

Fineline Cube Dec 23, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced receiving the...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval to Test SHR-1681 in Clinical Trials

Fineline Cube Dec 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval from...

Company Drug

CSPC Pharmaceutical’s SYH9017 Receives NMPA Clearance for Weight Management Clinical Trial

Fineline Cube Dec 23, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced clinical clearance from the National...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for Two Antibody-Drug Conjugates

Fineline Cube Dec 23, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received separate...

Company Drug

CanSino Biologics Initiates Phase I/II Study for CS-2036 Polio Vaccine with Gates Foundation Support

Fineline Cube Dec 23, 2024

CanSino Biologics (SHA: 688185, HKG: 6185) has announced the initiation of a Phase I/II study...

Company Drug

Innovent Biologics’ Taletrectinib Wins NMPA Approval for ROS1+ NSCLC Treatment

Fineline Cube Dec 23, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving marketing approval from the National Medical...

Company Medical Device

MicroPort Scientific Corp. Receives NMPA Approval for FireRaptor Coronary Atherectomy System

Fineline Cube Dec 23, 2024

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...

Company

Biopharma Company TransThera Sciences (Nanjing) Gets Green Light for HK IPO

Fineline Cube Dec 22, 2024

On December 20, 2024, the China Securities Regulatory Commission confirmed the listing filing for TransThera...

Company Drug

YolTech Therapeutics’ YOLT-201 Advances in ATTR Treatment Clinical Trial

Fineline Cube Dec 21, 2024

Shanghai, China, December 21, 2024 — YolTech Therapeutics today announced that its proprietary in vivo...

Posts pagination

1 … 188 189 190 … 613

Recent updates

  • Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up
  • Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study
  • Eisai/Biogen’s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer’s Dosing
  • HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance
  • Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Company Drug

Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study

Company Drug

Eisai/Biogen’s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer’s Dosing

Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.